Comparison of topical and intravenous administration of tranexamic acid for blood loss control during total joint replacement: Review of literature

Georgi P. Georgiev, Panayot P. Tanchev, Zlatka Zheleva, Plamen Kinov

Department of Orthopedics and Traumatology, University Hospital Queen Giovanna-ISUL, Medical University of Sofia, Bulgaria
Department of Anesthesiology and Intensive Care, University Hospital Queen Giovanna-ISUL, Medical University of Sofia, Bulgaria

Received 10 November 2017; received in revised form 11 December 2017; accepted 28 December 2017
Available online 20 January 2018

Abstract
Purpose: Many randomised controlled trials and meta-analysis studies have presented the efficacy of tranexamic acid (TXA) without an increase of complications. However, questions still remain about the type of administration, optimal dose and secondary outcomes of TXA in total hip arthroplasty and total knee arthroplasty. The aim of this review is to summarise the existing information in literature concerning the pharmacological characteristics of TXA, forms, doses, types of application and contraindications for its use.

Methods: A literature review containing 63 articles from the PubMed data starting from the first description of tranexamic acid until now was made in trying to present the existing information in a simple and effective way.

Results: TXA leads to statistically significant reduction of peri and postoperative bleeding and in that way decreases blood transfusion rates and the infection risk. Topical and intravenous (IV) use of TXA revealed similar results, with no increase of deep venous thrombosis. Therefore, topical TXA could be a reasonable alternative in patients with contraindications for IV application of TXA.

Conclusions: Blood loss control with TXA, a synthetic analogue of the amino acid lysine, may be an excellent and safe alternative to allogeneic blood transfusion after total hip arthroplasty and total knee arthroplasty. Further studies are needed to establish the efficacy of combined IV and topical administration of TXA with regard to diminishing blood loss and reducing hospital stay.

* Corresponding author. Department of Orthopaedics and Traumatology, University Hospital Queen Giovanna-ISUL, Medical University — Sofia, 8 Bialo more str., BG 1527 Sofia, Bulgaria
E-mail address: georgievgp@yahoo.com (G.P. Georgiev).
The Translational Potential of this Article: This review briefly presents the pharmacological characteristics of TXA, forms, doses, types of application and contraindications for its use with regard to diminishing blood loss and reducing hospital stay for better therapeutic strategies in orthopaedics.

Introduction

Total hip arthroplasty (THA) is the most common operative procedure for osteoarthritis. It is associated with high perioperative blood loss between 700 mL and 2,000 mL, which leads to a longer hospital stay, impedes rehabilitation and may be poorly tolerated by patients with cardiovascular diseases. It is estimated that 65% of blood loss in THA occurs within the first 8 hours after surgery and often leads to significant postoperative anaemia [1]. For this reason, many patients need peri or postoperative blood transfusion. Commonly, 11–67% of the patients undergo blood transfusion [2,3], which increases the high economic costs of the procedure and could provoke an anaphylactic reaction, heart or renal failure and infectious disease [4–6].

Different blood-conserving techniques, such as autologous blood transfusion [7] or autologous fibrin tissue application [8], have been used in clinical practice to reduce the postoperative blood transfusion rates [9]. Autologous transfusion reduces the risks of infection, but is also expensive. To minimise blood loss, hypotensive anaesthesia is also used [10]. Another method for control of the perioperative blood loss is the application of antifibrinolytic agents including aprotinin, tranexamic acid (TXA) and epsilon-a-macroglobulin acid. Among them, TXA has attracted the most attention [11–13].

Currently, in literature, there are numerous studies presenting the efficacy of TXA in reducing blood loss with no increase of complications. However, questions still remain about the type of administration, optimal dose and secondary outcomes of TXA in THA and total knee replacement (TKA). Herein, we reviewed the current literature on the pharmacological characteristics, forms, doses, types of application and contraindications for the use of TXA. The effects on blood coagulation of topically or intravenously administered tranexamic acid were evaluated.

TXA characteristics

TXA is a trans-stereoisomer of a synthetic amino acid with a molecular weight of 157 g/mol [14] which serves as an inhibitor of fibrinolysis and an activator of plasminogen. In 1962, for the first time, Okamoto et al [15] and Melander et al [16] independently described TXA. They discovered that the trans-form of 4-(aminomethyl)-cyclohexane-carboxylic acid had antifibrinolytic properties. It is a white powder that forms crystals, which are soluble in water, acids and alkalis and slightly soluble in alcohol, but remain insoluble in organic solvents. Although described in 1962, the first study that indicated its efficacy after THA was presented [18]. There are different studies, which revealed that the administration of TXA reduced the postoperative blood loss and the blood transfusion rates after THA [19,20]. In vitro studies reveal that TXA is 10 times more effective in reducing blood loss than aminocaproic acid. TXA is distributed throughout all body tissues, and its plasma half-life is 120 minutes [21]. After application, TXA levels are highest in the liver, kidneys and lungs. TXA is mainly eliminated through the renal system. Therefore, the doses of TXA in renal diseases should be corrected according to the levels of the creatinine in plasma. The recommended doses are according to the glomerular filtration rate (GFR): 50 mL/min, 50% of dose, GFR 10–50 mL/min, 25% of dose and GFR 10 mL/min, 10% of dose [22,23]. In contrast, in hepatic diseases, the dose does not need to be corrected due to the fact that the liver metabolises only a small amount of TXA [22].

Forms and doses of TXA

TXA is available in different forms: intravenous (IV), topical and oral. Each form needs different time to reach maximum plasma levels [5–15 min for IV injection, 30 min for intramuscular injection and 2 h for oral administration] [24]. Dahl et al [25] reported that the fibrinolytic response occurs in the early phases of operative procedures. TXA requires time for plasminogen to be activated.

Usually, doses used in hip and knee arthroplasty have been lower than doses for cardiac surgery, menstrual bleeding or in neurosurgery [26]. The dose of IV TXA in THA is 10–15 mg/kg or 1 g of TXA for IV use and 1–3 g for topical use, around 5 minutes before the skin incision. Benoni et al [27] reported that 3 hours after IV administration, the concentration of TXA in the plasma is above the minimum therapeutic level. Konig et al [28] and Yue et al [29] recommend that the dose of topically administered TXA be >2 g so it can play its role in reducing blood loss and transfusion rate.

It is estimated that only a small percentage of the IV injected TXA reaches the target location to inhibit tissue fibrinolysis and stabilise the clot, thus reducing bleeding [12]. It should be pointed out that the total blood loss and transfusion rate were not reduced with higher doses of TXA [12].

TXA in orthopaedics and trauma patients

Hiippala et al [30] presented one of the first randomised studies evaluating the efficacy of TXA in reducing blood loss
in TKA. In their study of 75 patients, the authors demonstrated that in a group of TKA, there was a significant reduction of blood loss. Poeran et al [31] also reported the efficacy of IV TXA in a retrospective cohort study based on 872,416 THA and TKA procedures. Reports from the Clinical Randomisation of Antifibrinolytics in Significant Haemorrhage trial have shown the results after IV application of TXA in 20,211 trauma patients. In the group of IV TXA, a significant reduction of thrombotic events and arterial thrombosis without an increased risk of venous thromboembolic events were observed [32].

Different authors report that the local application of TXA significantly reduces haemoglobin decrease and total blood loss [28,33–35]. Sukeik et al [12] reviewed a total of seven studies (comprising 350 patients) and established that TXA reduced intraoperative blood loss by 104 mL, postoperative blood loss by 172 mL and total blood loss by a mean of 289 mL. Na et al [33] reported that after THA, the fibrinolysis in the postoperative period could be reduced by TXA, which may lead to lower postoperative blood loss. However, the effect of TXA in reducing the need for blood transfusion is controversial. Some authors report a 14–20% reduction [28,34], whereas others report no difference [35,36].

**IV application of TXA**

IV application of TXA is the most common way of administration in TKA and THA. TXA is distributed in the extracellular and intracellular spaces and reaches a high plasma concentration. Andersson et al [37] stated that after IV injection of 10 mg/kg of TXA, the plasma levels were highest within 1 hour. Thirty percentage of TXA was excreted in the urine after 1 hour, 55% at 3 hours and 90% after 24 hours. The half-life of TXA was reported to be between 80 minutes and 120 minutes. Moreover, 15 minutes after IV application, TXA reaches similar levels in the synovial fluid as in plasma [37].

Different ways of IV TXA, such as prolonged infusion, repeated boluses and boluses at induction or closure, have been used in clinical practice [38]. The used doses of TXA are 10–30 mg/kg or 1–2 g. It should be pointed out that the time of application is also of importance. When used at the end of the procedure and 3 hours later, TXA did not reduce total blood loss [9].

**Local administration of TXA**

Local administration of TXA in the joint or periarticular tissue during closure has also been reported [38]. TXA stops fibrin clot dissolution and, in that way, allows better haemostasis. The plasma levels of topical TXA are around 70% lower than those after IV administration. The levels of TXA in plasma after low (1.5 g) and high (3.0 g) doses are 4.5 mg/L and 8.5 mg/L, respectively, whereas the plasma level 1 hour after 10 mg/kg of IV TXA was 18 mg/L [39].

Molloy et al [40] reported that TXA has a biological half-life of 2–3 hours within joint fluid. Sun et al [41] reported that the intraarticular use of TXA can minimise haemoglobin decrease, the need for blood transfusion and total blood loss. No significant difference in the occurrence of infection, deep venous thrombosis (DVT) or other adverse events has been reported. Locally applied, TXA has the advantage to directly affect the bleeding site, and thus reduces blood loss. The intraarticular injection of TXA is easy for application and also provides a high local concentration and diminished joint swelling and permits advanced wound healing and rapid rehabilitation [42,43]. Lin et al [44] reported that intraarticular TXA reduces the separation of drainage within the first 8 hours. In spite of this, no significant difference after 8 hours was reported. According to Martin et al [35] and Wind et al [36], local administration of TXA reduces blood loss and the transfusion rate but this is not statistically significant. In cases of higher amount of drainage fluid, a new application of TXA should be performed. Xu et al [1] reported that the preoperative use of TXA also has benefits.

Other routes of TXA administration also include oral and muscular forms. Via these routes, TXA reaches maximum plasma levels at 2–3 hours and 0.5 hour, respectively [45]. The doses are usually divided preoperatively and postoperatively. They have been established as low as 1.95 g by Fillingham et al [46] and as high as 6 g by Bradshaw et al [47]. Fillingham et al [46] after comparison of oral TXA and IV TXA in TKA found that oral TXA provided equivalent reductions in blood loss to IV at a cost of $14 compared with $47–$108 depending on the IV formulation selected. However, further studies need to reveal their efficiency and safety in THA and TKA, but it definitely seems that they are one of the most cost-effective methods.

**Comparison between local and IV application**

Present studies have demonstrated that there is no difference between wound irrigation and intraarticular injection at the time of surgery compared with IV administration of TXA [13,28,35,36]. Topical administration was also safer in patients with risk of venous thromboembolism (VTE) and also was more cost-effective; it also minimised the risk of systemic complications. [28,35,36,48]. The topical injection induced partial microvascular haemostasis by inhibiting the dissolution of fibrin clots in the affected area [49]. Machin et al [38] in their nonrandomised study did not observe any advantage to use topical TXA at wound closure together with IV TXA at the start of the operation. Martin et al [35] and Wind et al [36] considered that IV administration was better with more predictable results of maximal effect on diminishing blood loss. Ueno et al [13] reported that in THA, TXA reduced postoperative and total blood loss. The authors did not find significant differences between the type of administration connected to blood loss, haemoglobin levels, transfusion rates and systemic complications. However, they established that there was a difference in the amount of TXA between the topical (2 g) and IV (1 g) groups. Liu et al [50] in their meta-analysis study in patients after THA reported that the combined application of IV and topical TXA reduced the total blood loss compared with IV use alone. Moreover, they did not report an increased risk of complications. The relative disadvantage of combined TXA application is the prolonged operative time needed for joint injection. Meena et al [51] in their meta-analysis study examined eight randomised
clinical trials with 857 patients for the efficacy and safety of intraarticular TXA compared with IV route. These authors found that topical TXA has a similar efficacy to IV TXA in reducing total blood loss, drain output, transfusion rate and haemoglobin drop without any increase in thromboembolic complications. Li et al [52] evaluated 2056 patients after THA in their systematic review and meta-analysis study and established that topical TXA had a similar efficacy compared with IV TXA. No significant difference was found between topical and IV application of TXA regarding the blood loss, the transfusion rates, the haemoglobin drop and the thromboembolic complications. According to these authors, the advantages of topical use of TXA were as follows: easy application, reduced costs, lower systemic absorption and direct effect to the bleeding sites. Lin et al [53] in their meta-analysis study presented the results after using TXA in patients undergoing TKA. The authors found that after combined topical and intravenous administration, TXA decreased the total blood loss and the blood transfusion rates. However, they established that there is no significant difference between combined topical and intravenous TXA compared with topical or intravenous TXA. In addition, no increase in developing DVT was established. Chen et al [54] after reviewing 16 randomised controlled trials with 1,250 patients undergoing TKA and four randomised controlled trials involving 550 patients undergoing THA concluded that there was no significant difference between using topical and IV TXA in reducing blood loss or transfusion rate.

Contraindications for TXA application

There are no clear contraindications for TXA application apart from allergic reactions, history of venous or arterial thrombosis, acute renal failure, subarachnoid haemorrhage and seizure disorder [55]. The increased incidence of seizure disorders could be explained by the fact that TXA crosses the blood-brain barrier and interacts with glycine receptors [56]. Postoperative seizures have been reported in patients with renal dysfunction after high doses of TXA (50 mg/kg). In the current orthopaedic literature, there are no reports of seizures after usage of TXA. Colour vision impairment and visual disturbances could also be caused by the use of TXA. After literature review, we do not find studies indicating that different routes of application of TXA may provoke increased complications rates. According to Gilbody et al [34], the topical use of TXA could be safer than IV in patients with increased risk of thromboembolic events or with renal impairment. This is probably due to the fact that after local administration, the absorption rate from the joint is very low.

Reduction of hospital stay and risk of DVT and infection

TXA reduces the length of hospital stay by 0.6–1 day [28,34] with minimal or no increase in infection or venous thromboembolic events [28,35,36]. Different meta-analysis studies did not establish an increased risk of VTE, infection or adverse outcome after application of TXA [20,57–61]. However, Emara et al [62] reported a higher prevalence of DVT, pulmonary embolism and cerebrovascular events/strokes in patients after IV TXA in hemiarthroplasty. It should be mentioned that the IV administration of TXA decreases external blood loss but not hidden blood loss [63].

Conclusion

In conclusion, numerous prospective randomised controlled and meta-analysis studies have reported that TXA leads to statistically significant reduction of perioperative and postoperative bleeding and, in that way, decreases the blood transfusion rates and the infection risk during THA and TKA. Moreover, TXA is safe and does not increase the VTE rates. From the economical point of view, TXA is cost-effective and reduces the length of hospital stay. Topical and IV use of TXA revealed similar results, with no increase of DVT. Therefore, topical TXA could be a reasonable alternative in patients with contraindications for IV application of TXA. Further studies are needed to establish the efficacy of combined IV and topical administration of TXA with regard to diminishing blood loss and reducing hospital stay and to elucidate whether TXA reduces complication rates and improves postoperative recovery and whether different types of administration correspond with increased complications rates.

Author contributions

All authors conceptualised the study and participated in study screening, selection, data extraction and manuscript preparation. All authors provided intellectual content and approved the manuscript for publication.

Conflicts of interest

The authors declared that there is no conflict of interest.

Funding

The authors have nothing to disclose.

Acknowledgments

The authors are very indebted to Dr Georgi Kotov for his kind proofreading of the English text.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.jot.2017.12.006.

References

[1] Xu HD, Zhou ZK, Pei FX, Hu X, Zhou Z, Pei F, et al. Perioperative efficiency and safety of different regimen of tranexamic acid on total knee arthroplasty. Chin J Orthop 2014;34:599–604.
Tranexamic acid in total joint replacement

[2] Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 1999;81:2–10.

[3] Toy PT, Kaplan EB, McVay PA, Lee SJ, Strauss RG, Stehling LC. Blood loss and replacement in total hip arthroplasty: a multicenter study. The preoperative autologous blood donation study group. Transfusion 1992;32:63–7.

[4] Friedman R, Homerling M, Holberg G, Berkowitz SD. Allogeneic blood transfusions and postoperative infections after total hip or knee arthroplasty. J Bone Joint Surg Am 2014;96:272–8. https://doi.org/10.2106/JBJS.L.01268.

[5] Lemaire R. Strategies for blood management in orthopaedic and trauma surgery. J Bone Joint Surg Br 2008;90:1128–36. https://doi.org/10.1302/0301-620X.90B13.21115.

[6] Varney SJ, Guest JF. The annual cost of blood transfusions in the UK. Transfus Med Aug 2003;13:205–18.

[7] Woolson ST, Marsh JS, Tanner JB. Transfusion of previously deposited autologous blood for patients undergoing hip-replacement surgery. J Bone Joint Surg Am 1987;69:325–8.

[8] Mawatari M, Higo T, Tsutsumi Y, Shigematsu M, Hotokebuchi T. Effectiveness of autologous fibrin tissue adhesive in reducing postoperative blood loss and during total hip arthroplasty: a prospective randomised study of 100 cases. J Orthop Surg (Hong Kong) 2006;14:117–21. https://doi.org/10.1177/230949006014002002.

[9] Benoni G, Lethagen S, Nilsson P, Fredin H. Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty. Acta Orthop Scand 2000;71:250–4. https://doi.org/10.2340/00016470.1999.7104.250.

[10] Conteduca F, Massai F, Iorio R, Zanzotto E, Luzon D, Ferretti A. Blood loss in computer-assisted mobile bearing total knee arthroplasty. A comparison of computer-assisted surgery with a conventional technique. Int Orthop 2009;33:1609–13. https://doi.org/10.1007/s00264-008-0651-7.

[11] Keyhani S, Esmailejeh AA, Abbasian MR, Saffari F. Which route of tranexamic acid administration is more effective to reduce blood loss following total knee arthroplasty? Arch Bone Jt Surg 2016;4:65–9.

[12] Sukeik M, Alshryda S, Haddad FS, Mason JM. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br 2011;93:39–46. https://doi.org/10.1302/0301-620X.93B1.23131.

[13] Ueno M, Sonohata M, Kawano S, Kitajima M, Mawatari M. Comparison between topical and intravenous administration of tranexamic acid in primary total hip arthroplasty. J Orthop Sci 2016;21:44–7. https://doi.org/10.1016/j.jos.2015.10.011.

[14] Boling B, Moore K. Tranexamic acid (TXA) use in trauma. J Emerg Nurs 2012;38:496–7. https://doi.org/10.1016/j.jen.2012.06.001.

[15] Okamoto S, Sato S, Takada Y, Okamoto U. An active stereo-isomer (trans-form) of AMCHA and its antifibrinolytic (anti-plasminic) action in vitro and in vivo. Keio J Med 1964;13:177–85.

[16] Melander B, Gliniecki G, Granstrand B, Hanshoff G. Biochemistry and toxicology of amikapron; the antifibrinolytically active isomer of AMCHA. (A comparative study with epsilon-aminocaproic acid). Acta Pharmacol Toxicol (Copen) 1965;22:340–52.

[17] Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999;57:1005–32.

[18] Ekbäck G, Axelsson K, Ryttberg L, Edlund B, Kjellberg J, Weckström, et al. Tranexamic acid reduces blood loss in total hip replacement surgery. Anesth Analg 2000;91:1124–30.

[19] Ralley FE, Bertà D, Binns V, Howard J, Naudie DD. One intraoperative dose of tranexamic acid for patients having primary hip or knee arthroplasty. Clin Orthop Relat Res 2010;468:1905–11. https://doi.org/10.1007/s11999-009-1217-8.

[20] Oremus K, Sostaric S, Trkulja V, Haspl M. Influence of tranexamic acid on postoperative autologous blood retransfusion in primary total hip and knee arthroplasty: a randomized controlled trial. Transfusion 2014;54:31–41. https://doi.org/10.1111/trf.12224.

[21] Hunt BJ. The current place of tranexamic acid in the management of bleeding. Anaesthesia 2015;70:30–3. https://doi.org/10.1111/anae.12910.

[22] McIntyre CW, Owen P.J. Prescribing drugs in kidney disease. In: Brenner BM, editor. Brenner and Rector’s the kidney. 8th ed. PA: Saunders, Philadelphia; 2008. p. 1930–53.

[23] Flechtnier BK, Nuttall GA, Johnson ME, Dong Y, Sujirattanawimol N, Oliver Jr WC, et al. Plasma tranexamic acid concentrations during cardiopulmonary bypass. Anesth Analg 2001;92:1131–6.

[24] Soni A, Saini R, Gulati A, Paul R, Bhatta S, Rajoli SR. Comparison between intravenous and intra-articular regimens of tranexamic acid in reducing blood loss during total knee arthroplasty. J Arthroplasty 2014;29:1525–7. https://doi.org/10.1016/jarth.2014.03.039.

[25] Dahl OE, Pedersen T, Kierulf P, Westvik A, Lund P, Arnesen H, et al. Sequential intrapulmonary and systemic activation of coagulation and fibrinolysis during and after total hip replacement surgery. Thromb Res 1993;70:451–8.

[26] McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs 2012;72:585–617. https://doi.org/10.2165/11209070-000000000-00000.

[27] Benoni G, Carlsson A, Petersson C, Fredin H. Does tranexamic acid reduce blood loss in knee arthroplasty? Am J Knee Surg 1995;8:88–92.

[28] Konig G, Hamlin BR, Waters JH. Topical tranexamic acid reduces blood loss and transfusion rates in total hip and total knee arthroplasty. J Arthroplasty 2013;28:1473–6. https://doi.org/10.1016/j.arth.2013.06.011.

[29] Yue C, Kang P, Yang P, Xie J, Pei F. Topical application of tranexamic acid in primary total hip arthroplasty: a randomized double-blind controlled trial. J Arthroplasty 2014;29:2452–6. https://doi.org/10.1016/j.arth.2014.03.032.

[30] Hiippala ST, Strid LJ, Wennerscheidt M, Arvela JV, Niemelä HM, Mäntylä SK, et al. Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty. Anesth Analg 1997;84:839–44.

[31] Poeran J, Rasul R, Suzuki S, Danninger T, Mazumdar M, Opperer M, et al. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ 2014;349:g4829. https://doi.org/10.1136/bmj.g4829.

[32] CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010;376:23–32. https://doi.org/10.1016/S0140-6736(10)60835-5.

[33] Na HS, Shin HJ, Lee YJ, Kim JH, Koo KH, Do SH. The effect of tranexamic acid on blood coagulation in total hip replacement arthroplasty: rotational thromboelastographic (ROTEM®) analysis. Anaesthesia 2016;71:67–75. https://doi.org/10.1111/anae.13270.

[34] Gilbody J, Dhotar HS, Perruccio AV, Davey JR. Topical tranexamic acid reduces transfusion rates in total hip and knee arthroplasty. J Arthroplasty 2014;29:681–4. https://doi.org/10.1016/j.arth.2013.09.005.

[35] Martin JG, Cassatt KB, Kincaid-Cinnamon KA, Westendorf DS, Garton AS, Lemke JH. Topical administration of tranexamic acid in primary total hip and total knee arthroplasty. J
Arthroplasty 2014;29:889–94. https://doi.org/10.1016/j.arth.2013.10.005.

[36] Wind TC, Barfield WR, Moskal JT. The effect of tranexamic acid on transfusion rate in primary total hip arthroplasty. J Arthroplasty 2014;29:387–9. https://doi.org/10.1016/j.arth.2013.05.026.

[37] Andersson L, Nilsson IM, Niléhn JE, Hedner U, Granstrand B, Melander B. Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid. Scand J Haematol 1965;2:230–47.

[38] Machin JT, Batta V, Soler JA, Sivaganam K, Kalairajah Y. Comparison of intra-operative regimes of tranexamic acid administration in primary total hip replacement. Acta Orthop Belg 2014;80:228–33.

[39] Nilsson IM. Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol) 1980;14:41–7.

[40] Molloy DO, Archbold HA, Ogonda L, McConway J, Wilson RK, Beverland DE. Comparison of topical fibrin spray and tranexamic acid on blood loss after total knee replacement: a prospective, randomised controlled trial. J Bone Joint Surg Br 2007;89:306–9. https://doi.org/10.1302/0301-660X.89B5.17565.

[41] Sun X, Dong Q, Zhang YG. Intravenous versus topical tranexamic acid in primary total hip replacement: a systemic review and meta-analysis. Int J Surg 2016;32:10–8. https://doi.org/10.1016/j.ijjsu.2016.05.064.

[42] Patel VP, Walsh M, Selgah B, Preston C, DeWalt H, Di Cesare PE. Factors associated with prolonged wound drainage after primary total hip and knee arthroplasty. J Bone Joint Surg Am 2007;89:33–8. https://doi.org/10.2106/JBJS.F.00163.

[43] Ishida K, Tsumura N, Kitagawa A, Hamamura S, Fukuda K, Dogaki Y, et al. Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty. Int Orthop 2011;35:1639–45. https://doi.org/10.1007/s00167-011-1731-8.

[44] Lin PC, Hsu CH, Chen WS, Wang JW. Does tranexamic acid save blood in minimally invasive total knee arthroplasty? Clin Orthop Relat Res 2011;469:1995–2002. https://doi.org/10.1007/s11999-011-1789-y.

[45] Wong J, Abrishami A, El Beheiry H, Mahomed NN, Roderick Dadvay J, Gandhi R, et al. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J Bone Joint Surg Am 2010;92:2503–13. https://doi.org/10.2106/JBJS.I.01518.

[46] Fillingham YA, Kayoupol E, Plummer DR, Moric M, Gerlinger TL, Della Valle CJ. The James A. Rand Young Investigator’s Award: a randomized controlled trial of oral and intravenous tranexamic acid in total knee arthroplasty: the same efficacy at lower cost? J Arthroplasty 2016;31:26–30. https://doi.org/10.1016/j.arth.2016.02.081.

[47] Bradshaw AR, Monaghan J, Campbell D. Oral tranexamic acid reduces blood loss in total knee replacement arthroplasty. Current Orthop Pract 2012;23:209–12. https://doi.org/10.1097/BCO.0b013e318247f1d5.

[48] Patel JN, Spanyer JM, Smith LS, Huang J, Yakkanti MR, Malkani AL. Comparison of intravenous versus topical tranexamic acid in total knee arthroplasty: a prospective randomized study. J Arthroplasty 2014;29:1528–31. https://doi.org/10.1016/j.arth.2014.03.011.

[49] Seo JG, Moon YW, Park SH, Kim SM, Ko KR. The comparative efficacies of intra-articular and IV tranexamic acid for reducing blood loss during total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc 2013;21:1869–74. https://doi.org/10.1007/s00167-012-2079-2.

[50] Liu X, Liu J, Sun G. A comparison of combined intravenous and topical administration of tranexamic acid with intravenous tranexamic acid alone for blood loss reduction after total hip arthroplasty: a meta-analysis. Int J Surg 2017;41:34–43. https://doi.org/10.1016/j.ijsu.2017.03.031.

[51] Meena S, Benazzo F, Dwivedi S, Ghara M. Topical versus intravenous tranexamic acid in total knee arthroplasty. J Orthop Surg (Hong Kong) 2017;25, 2309499016684300. https://doi.org/10.1177/2309499016684300.

[52] Li J, Zhang Z, Chen J. Comparison of efficacy and safety of topical versus intravenous tranexamic acid in total hip arthroplasty: a meta-analysis. Medicine (Baltimore) 2016;95:e4689. https://doi.org/10.1097/MD.0000000000004689.

[53] Lin C, Qi Y, Jie L, Li HB, Zhao XC, Qin L, et al. Is combined topical with intravenous tranexamic acid more efficacious than topical, intravenous tranexamic acid alone and control groups for blood loss controlling after total knee arthroplasty: a meta-analysis. Medicine (Baltimore) 2016;95:e5344. https://doi.org/10.1097/MD.0000000000005344.

[54] Chen Y, Chen Z, Cui S, Li Z, Yuan Z. Topical versus systemic tranexamic acid after total knee and hip arthroplasty: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2016;95:e4656. https://doi.org/10.1097/MD.0000000000004656.

[55] Tengborn L, Blomback M, Berntorp E. Tranexamic acid—an old drug still going strong and making a revival. Thromb Res 2015;135:231–42. https://doi.org/10.1016/j.thromres.2014.11.012.

[56] Lecker I, Wang DS, Rosmachin AD, Peterson M, Mazzer CD, Orser BA. Tranexamic acid concentrations associated with human seizures inhibit glycine receptors. J Clin Invest 2012;122:4654–66. https://doi.org/10.1172/JCI63375.

[57] Alshryda S, Sarda P, Sukelik M, Nargol A, Blenkinsopp J, Mason JM. Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg Br 2011;93:1577–85. https://doi.org/10.1302/0301-620X.93B12.26989.

[58] Tan J, Chen H, Liu Q, Chen C, Huang W. A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty. J Surg Res 2013;184:880–7. https://doi.org/10.1016/j.jss.2013.03.099.

[59] Huang Z, Ma J, Shen B, Pei F. Combination of intravenous and topical application of tranexamic acid in primary total knee arthroplasty: a prospective randomized controlled trial. J Arthroplasty 2014;29:2342–6. https://doi.org/10.1016/j.arth.2014.05.026.

[60] Duncan CM, Gillette BP, Jacob AK, Sierra RJ, Sanchez-Sotelo J, Smith HM. Venous thromboembolism and mortality associated with tranexamic acid use during total hip and knee arthroplasty. J Arthroplasty 2015;30:272–6. https://doi.org/10.1016/j.arth.2014.08.022.

[61] Lemay E, Guay J, Côté C, Roy A. Tranexamic acid reduces the need for allogenic red blood cell transfusions in patients undergoing total hip replacement. Can J Anaesth 2004;51:31–7. https://doi.org/10.1007/BF03018543.

[62] Emara WM, Moez KK, Elkhouly AH. Topical versus intravenous tranexamic acid as a blood conservation intervention for reduction of post-operative bleeding in hemiarthroplasty. Anesth Essays Res 2014;8:48–53. https://doi.org/10.4103/0975-1162.128908.

[63] Good L, Peterson E, Lisander B. Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement. Br J Anaesth 2003;90:596–9.